NEWS HIGHLIGHTSMedia Articles Related to Oxyir (Oxycodone)
Oxycodone May Reduce Shingles Pain
Source: MedicineNet Chickenpox (Varicella) Specialty [2009.04.13]
Title: Oxycodone May Reduce Shingles Pain
Category: Health News
Created: 4/11/2009 2:00:00 AM
Last Editorial Review: 4/13/2009
62-Year-Old Man Becomes First Patient In China Implanted With Rechargeable Neurostimulator For Chronic Pain
Source: Health News from Medical News Today [2009.11.19]
St. Jude Medical, Inc. (NYSE:STJ) announced that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.
Common Pain Relief Medication May Encourage Cancer Growth
Source: Cancer / Oncology News From Medical News Today [2009.11.19]
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Two new studies advance that argument and demonstrate how shielding lung cancer cells from opiates reduces cell proliferation, invasion and migration in both cell-culture and mouse models.
CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference In San Francisco
Source: Clinical Trials / Drug Trials News From Medical News Today [2009.11.19]
CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA. Dr.
Transplanting People's Own Stem Cells Into Heart Lessens Pain, Improves Ability To Walk
Source: Clinical Trials / Drug Trials News From Medical News Today [2009.11.19]
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
Published Studies Related to Oxyir (Oxycodone)
Dexamethasone decreases oxycodone consumption following osteotomy of the first metatarsal bone: a randomized controlled trial in day surgery. [2009.10.10]
Background: Dexamethasone may improve multimodal pain management following painful orthopedic day surgery procedures, and decrease the need for post-operative opioids. We hypothesized that dexamethasone would reduce the need for oxycodone after surgical correction of hallux valgus... Conclusion: Oral dexamethasone combined with paracetamol significantly reduced total oxycodone consumption following surgical correction of hallux valgus.
A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. [2009.10]
INTRODUCTION: In this study, we investigated the dose requirements, pain relief, and side effects of oxycodone versus morphine after surgery with visceral pain... CONCLUSIONS: Oxycodone was more potent than morphine for visceral pain relief but not for sedation.
Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. [2009.09]
BACKGROUND: Peripherally selective opioids may be beneficial in visceral pain management due to absence of centrally mediated side effects. The objectives of this study were: (1) to assess the effects of a peripherally selective tetrapeptide kappa-opioid receptor agonist, CR665, on experimental pain from multi-modal stimulation of skin, muscle, and viscera, and (2) contrast these effects with those of oxycodone (centrally acting opioid)... CONCLUSION: CR665 had a selective effect on visceral pain. Oxycodone exhibited a generalized effect, elevating thresholds for cutaneous, deep somatic, and visceral pain stimulation.
Relationship between rate of infusion and reinforcing strength of oxycodone in humans. [2009.07]
The rate of drug delivery to the central nervous system is believed to be an important predictor of the reinforcing strength of a drug. However, only a few studies have directly examined the relationship between drug-taking behavior and rate of drug administration... Specifically, these "abuse-deterrent formulations" could prevent patients from tampering with their medications to enhance their euphoric and reinforcing effects.
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. [2009.06]
BACKGROUND: Oxycodone is a mu-opioid receptor agonist that is metabolized mainly in the liver by cytochrome P450 3A and 2D6 enzymes. Rifampin is a strong inducer of several drug-metabolizing enzymes. The authors studied the interaction of rifampin with oxycodone. Their hypothesis was that rifampin enhances the CYP3A-mediated metabolism of oxycodone and attenuates its pharmacologic effect... CONCLUSIONS: Induction of cytochrome P450 3A by rifampin reduced the area under the oxycodone concentration-time curve of intravenous and oral oxycodone. The pharmacologic effects of oxycodone were modestly attenuated. To maintain adequate analgesia, dose adjustment of oxycodone may be necessary, when used concomitantly with rifampin.
Clinical Trials Related to Oxyir (Oxycodone)
Oxycodone-Naloxone Prolonged Release Tablets in Relieving Opioid-Related Constipation [Active, not recruiting]
Oxycodone-Naloxone in Relieving Opioid-Related Constipation [Active, not recruiting]
The primary objective of this study is to demonstrate that subjects with moderate to severe
non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in
symptoms of constipation compared to subjects taking oxycodone prolonged release tablets
alone.
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse [Recruiting]
The purpose of this study is: (1) to assess the effect of oxycodone HCl on niacin-induced
dysphoric effects when oxycodone HCl is administered in combination with niacin in subjects
with a history of opioid abuse; (2) to assess the abuse liability of 4 times the usual
recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40
mg alone in subjects with a history of opioid abuse.
A Study Of RN624 (PF-04383119) And Oxycodone In Patients With Pain Due To Cancer That Has Spread To Bone [Recruiting]
The purpose of this study is to investigate whether RN624 (alone and in combination with
oxycodone) is safe and effective in treating pain due to cancer that has spread to bone.
OXY-1: The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain [Completed]
Patients undergoing surgery (thyroidectomy and hysterectomy) will postoperatively receive
oxycodone intravenously (IV) as pain management with morphine as an escape medicine, if there
is insufficient pain relief with oxycodone. Patients' pain and side effects will be
registered and after 24 hours they will answer a questionnaire. All included patients will be
genotyped accordingly to CYP2D6 and relevant single nucleotide polymorphisms (SNPs), and
measures of plasma levels of oxycodone will be performed.
|
